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Abstract
Purpose—The choice of propensity score (PS) implementation influences treatment effect
estimates not only because different methods estimate different quantities, but also because
different estimators respond in different ways to phenomena such as treatment effect heterogeneity
and limited availability of potential matches. Using effectiveness data, we describe lessons learned
from sensitivity analyses with matched and weighted estimates.
Methods—With subsample data (N=1,292) from Sequenced Treatment Alternatives to Relieve
Depression, a 2001–2004 effectiveness trial of depression treatments, we implemented PS
matching and weighting to estimate the treatment effect in the treated and conducted multiple
sensitivity analyses.
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Results—Matching and weighting both balanced covariates but yielded different samples and
treatment effect estimates (matched RR 1.00, 95% CI:0.75–1.34; weighted RR 1.28, 95% CI:0.97–
1.69). In sensitivity analyses, as increasing numbers of observations at both ends of the PS
distribution were excluded from the weighted analysis, weighted estimates approached the
matched estimate (weighted RR 1.04, 95% CI 0.77–1.39 after excluding all observations below
the 5th percentile of the treated and above the 95th percentile of the untreated). Treatment
appeared to have benefits only in the highest and lowest PS strata.
Conclusions—Matched and weighted estimates differed due to incomplete matching, sensitivity
of weighted estimates to extreme observations, and possibly treatment effect heterogeneity. PS
analysis requires identifying the population and treatment effect of interest, selecting an
appropriate implementation method, and conducting and reporting sensitivity analyses. Weighted
estimation especially should include sensitivity analyses relating to influential observations, such
as those treated contrary to prediction.
Keywords
Propensity score; matching; weighting; comparative effectiveness research; treatment effect
heterogeneity; treatment effect in the treated; sensitivity analysis
INTRODUCTION
Observational comparative effectiveness studies are vulnerable to selection bias and
confounding.1 Increasingly, researchers use propensity scores to address these threats.2 The
propensity score is a person’s probability of assignment to a particular treatment, given his
or her pre-treatment characteristics. A well-estimated propensity score can be used to
balance treatment and comparison groups on measured covariates,3 making estimates of the
average treatment effect unbiased under the assumption of no unmeasured confounding.4–6
Propensity scores can be implemented in a number of ways, including stratification,
matching, weighting, and covariance adjustment.3, 7–11 The choice of propensity score
implementation influences treatment effect estimates not only because different methods
estimate different quantities,12 but also because different estimators respond in different
ways to phenomena such as treatment effect heterogeneity8 and limited availability of
potential matches.13
In the current study, we used data from the Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) Study to examine the effect of medication augmentation versus
medication switching on remission from depression among patients whose initial citalopram
treatment had failed. This question interested us because only 30% of patients recover
through initial antidepressant treatment;14 medication monotherapy and medication
combinations are among the second-line treatment options,15 but the available evidence
about these strategies has limited generalizability.16 Further, it seemed reasonable to make
such a comparison because the original STAR*D study made randomized comparisons
among augmentation agents and among switch agents and found no difference within either
category.17, 18
Specifically, we intended to measure the effect of medication augmentation in the
population receiving augmentation. Given that some participants realistically were
candidates for only one of the two strategies (i.e., augmentation or switching), we had
greater interest in this treatment effect than in an estimate of the population average
treatment effect. To estimate the average treatment effect in the treated (ATT), we used both
matching without replacement and weighting by the odds (ATT or Standardized Mortality/
Morbidity Ratio [SMR] weights, described in detail below). Both estimators can be used to
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measure the treatment effect in the treated, but unless a match is available for every treated
observation, they may not yield similar estimates.13 Our final substantive findings appear in
a separate paper, which resulted from additional analyses and provides a thorough treatment
of the substantive aspects of the study.19 In the current paper we focus on the lessons
learned from sensitivity analyses with matched and weighted estimates.
METHODS
Sample and data
STAR*D compared prospectively several treatments for outpatients with non-psychotic
major depressive disorder who had an unsatisfactory response to one or more treatments.20
To simulate real-world care, treatment assignment followed an equipoise randomization
scheme in which patient choice could influence treatment selection.21 In STAR*D, patients
had clear preferences for treatment strategies, and patients who received augmentation
differed from those who switched antidepressants.22, 23 As a result, the original STAR*D
analyses used randomization to compare outcomes within the augment and switch arms, but
randomized comparisons between the two arms were not possible.
The initial sample included 4,041 participants representative of patients receiving depression
treatment in U.S. primary care and specialty clinics. Of those, 1,439 discontinued an
aggressive initial trial of citalopram due to side effects, lack of recovery after at least 9
weeks, or individual choice. We used a public-release dataset from the National Institute of
Mental Health to examine outcomes for the 1,292 participants who continued to the second
stage of the trial and either augmented their current antidepressant therapy (with bupropion
SR or buspirone; n=565) or switched antidepressants (to bupropion SR, sertraline, or
venlafaxine XR; n=727).
The Biomedical Institutional Review Board of the University of North Carolina at Chapel
Hill determined that the current study did not require its approval.
Statistical analysis
In this study of second-line depression treatment, the primary outcome was depression
remission, measured using the Quick Inventory of Depression Symptomatology-Self Report
(QIDS-SR16). Using the switch group as a comparator, we wished to compare the outcomes
experienced by the augment group to the outcomes they would have experienced if they had
switched medications instead. Because a crude comparison would likely be affected by
selection bias, we applied propensity score methods to balance the groups on pre-treatment
covariates. After addressing missingness, we used logistic regression to estimate propensity
scores, implemented propensity score matching3, 8, 24 and ATT weighting11, 25 to estimate
the treatment effect in the treated, and conducted several sensitivity analyses.
Most observations (82%) had a missing value on at least one variable in the analysis model,
making a complete-case analysis impractical and likely biased. However, the missing values
constituted only 5% of the values needed for analysis, which made it possible to build an
imputation model that provided good information about the missing data. We used the
expectation-maximization method in SAS PROC MI (SAS Institute, Cary, NC) to impute
missing values based on observed variable distributions.26–29 Although multiple imputation
would be the method of choice for a substantive analysis, we used a single imputed dataset
to compare methods and conduct sensitivity analyses.
The original STAR*D trial included rigorous measurement of about 100 variables
potentially associated with depression outcomes. Our propensity score model incorporated
47 demographic and clinical covariates selected based on theory and published evidence,
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plus 30 interaction terms iteratively selected to improve between-group covariate balance.
To seek a match for each augment observation, we employed a 5-to-1-digit greedy matching
algorithm,30 which made five passes through the treatment group in random order. On each
pass the algorithm performed caliper matching without replacement, examining potential
matches in random order. At the end of each pass, the caliper width was increased by a
factor of 10, so that it ranged from ±.000005 to ±.05. To allow weighted estimates, each
augment patient received a weight of 1 and each switch patient received a weight of ps/(1-
ps), where ps is the propensity score. This approach up-weights switch patients with a high
propensity for receiving augmentation and down-weights switch patients with a low
propensity for receiving augmentation, so that the weighted covariate distribution in the
switch group (the “untreated”) resembles the covariate distribution in the augment group
(the “treated”).11, 25, 31 The approach has been called “ATT” weighting for “Average
Treatment effect in the Treated;”32 “SMR” weighting because, like a standardized mortality/
morbidity ratio, it allows a counterfactual estimate of the treatment effect in the treated;25
and “weighting by the odds” because each observation from the comparison group is
weighted by its odds of receiving treatment, conditional on covariates.33 We measured
balance in the matched and weighted cohorts using the average standardized absolute mean
(ASAM) difference across the 47 covariates.11 We used additional balance measures
developed by Rubin34 to confirm that balance was acceptable after both matching and
weighting.
Sensitivity of treatment effect estimates to propensity score implementation—
In both the matched cohort and the weighted cohort, we estimated the effect of augmentation
on depression remission using the FREQ and SURVEYFREQ procedures in SAS. We also
assessed the sensitivity of the weighted results to extreme observations in two ways. First we
truncated extreme weights, which reduces variability in the treatment effect estimate and
provides a way to explore the tradeoff between bias and variance.35 We used several pairs of
cutoff values, corresponding to percentiles of the distribution of weights in the switch group
(the only group with varying weights): 0 and 100, 1 and 99, 5 and 95, 10 and 90, 25 and 75,
50 and 50. When a weight was more extreme than the nearest cutoff value, we made the
weight equal to the cutoff value. For example, when the cutoffs were percentiles 1 and 99,
weights below the first percentile were increased to equal the first percentile, and weights
above the 99th percentile were decreased to equal the 99th percentile. The first pair of cutoffs
implied no restriction on the weights; the last pair implied constant weighting (i.e., the crude
treatment effect estimate).
Next, instead of truncating extreme weights we excluded observations in the tails of the joint
propensity score distribution, based on cutoff values derived from observations treated
contrary to prediction.36 This exclusion, or trimming, removes observations treated contrary
to prediction as well as their counterparts in the other treatment group, thus yielding
unbiased estimates for a more restricted population. Again we used several pairs of cutoff
values: percentiles 0 and 100, 1 and 99, 2.5 and 97.5, 5 and 95. We applied the minimum
cutoff to the propensity score distribution in the augment group and the maximum cutoff to
the distribution in the switch group, excluding observations in both groups whose scores
were beyond the cutoffs. For example, when the cutoffs were 0 and 100, we excluded
observations whose propensity scores were lower than the augment group’s minimum or
higher than the switch group’s maximum. Thus, the first pair of cutoffs implies restriction to
the common support region, and subsequent pairs exclude additional observations at both
ends of the common (overlapping) propensity score distribution.
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Figure 1 shows the propensity score distributions in the original, matched, and weighted
cohorts. Before propensity score adjustment the augment and switch groups were dissimilar
with regard to the pre-treatment characteristics measured by the propensity score, and the
two distributions were skewed in opposite directions. Twenty-three percent of switch
participants had propensity scores below the augment group’s minimum propensity score,
and 2% of augment participants had propensity scores above the switch group’s maximum
propensity score.
The matching procedure selected a sample (n=538) from the middle of the propensity score
distribution. Many augment participants with high propensity scores were unmatched
(dotted line in center panel of Figure 1); these patients tended to have greater tolerance for
initial treatment and lower depressive severity after initial treatment.19 Unlike matching,
weighting forced the propensity score distribution of the switch group to resemble that of the
augment group. This was achieved mainly by up-weighting the few switchers with high
propensity scores. The effect of the weighting can be observed by comparing the left and
right panels of Figure 1. Both matching and weighting resulted in good covariate balance
(ASAM difference 0.20 before adjustment, 0.03 after matching, 0.02 after weighting).
The crude risk ratio for remission favored augmentation (RR: 1.41, 95% confidence interval
[CI]: 1.19 to 1.67). The propensity-score-matched risk ratio for remission indicated no
benefit for augmentation (RR: 1.00, 95% CI: 0.75 to 1.34), but after weighting, remission
appeared to be more likely for patients receiving treatment augmentation rather than
switching (RR: 1.28, 95% CI: 0.97 to 1.69).
Because extreme weights may give a large amount of influence to a few patients, we
assessed the sensitivity of the weighted estimates to truncation of extreme weights (Figure
2). Regardless of the cutoffs used, the weighted estimates remained in the 1.2 to 1.4 range.
We also assessed the sensitivity of the weighted estimates to the exclusion of patients in the
tails of the overlapping propensity score range. These tails include patients treated contrary
to prediction (i.e., switch observations with extremely large propensity scores and augment
observations with extremely small propensity scores) (Figure 2). We found that as
increasing numbers of these observations were excluded, along with their counterparts in the
other treatment group, the weighted estimates approached a risk ratio of 1.0 (close to the
matched estimate).
Finally, to increase our understanding of the sensitivity of the weighted estimates to extreme
observations and the difference between the matched and weighted estimates, we stratified
by propensity score decile and examined the heterogeneity of the treatment effect across
propensity score strata (Figure 3). Initially there were no augment observations in the lowest
decile, so we restricted to the common support region for this analysis. Relative to
switching, augmentation had little effect on remission except in the lowest stratum (RR:
2.36, 95% CI: 0.74 to 7.46, augment n = 5, switch n = 106) and in the highest stratum (RR:
3.65, 95% CI: 0.58 to 23.11, augment n = 103, switch n = 8).
DISCUSSION
We examined and compared propensity-score-matched and ATT-weighted treatment effect
estimates in a comparative effectiveness study. Although both the matching procedure and
the weighting procedure resulted in covariate balance, they yielded different estimates of the
treatment effect. Both 95% confidence intervals were consistent with the null hypothesis of
no treatment effect, but an estimated 28% increase in the probability of remission differs
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meaningfully from an estimate indicating no treatment effect. Three factors likely
contributed to these results: (1) due to incomplete matching, the matched and weighted
samples had different propensity score distributions and therefore represented different
populations; (2) the weighted estimates were sensitive to extreme observations; and (3)
augmentation appeared to benefit patients only in the highest and lowest propensity score
deciles.
When propensity score matching is incomplete, the matched sample represents a different
population than the ATT-weighted sample. The matched-sample estimate can then be
labeled as the “treatment effect in treated patients for whom matches could be found” or, in
the current study, the “treatment effect in augmentation patients who were candidates for
both augmentation and switching.” Although this population may be difficult to describe, it
includes only people who were candidates for both treatments, so the corresponding
treatment effect estimate may be more clinically relevant than the treatment effect among all
augmentation patients (some of whom might not realistically be candidates for switching) or
the treatment effect in the entire population (including patients in both groups who
realistically might be candidates for only one of the two treatments).
ATT weighting, in contrast to matching, forces the propensity score distribution in the
untreated to be the same as the propensity score distribution in the treated. This method
clearly leads to an estimate of the average treatment effect in the treated, but the estimate
will be sensitive to extreme observations. If two dissimilar groups are being compared, then
ATT weighting constitutes extrapolation. In this case it is important to consider the meaning
of the effect being estimated and the degree to which the data support such an estimate. In
the current study, the ATT-weighted estimate represented the treatment effect in the
augment group, but this estimate required the up-weighting of the few switch participants
with high propensity scores, and the estimate was sensitive to the exclusion of these
observations.35, 37–40
If the treatment effect were completely uniform, then the choice of estimator would be
inconsequential. In the current example, treatment effect heterogeneity appeared to
contribute to the difference between the matched and weighted estimates. An alternative
explanation would be unmeasured confounding among patients in the tails of the propensity
score distribution. Our propensity score model included a large group of covariates that were
carefully selected and measured, providing protection from unmeasured confounding.
However, the apparently strong benefit of augmentation among patients unlikely to receive
augmentation defies explanation. Therefore, unmeasured confounding cannot be ruled out.
Alternatively, the apparent treatment effect heterogeneity may have been due to chance.
Very few patients in the highest propensity score decile switched medications, and very few
in the lowest decile received augmentation, leading to wide confidence intervals for these
estimates. In any case, caution must be exercised when interpreting treatment effect
estimates for areas of limited overlap on the propensity score, because these estimates are
sensitive to misspecification in the propensity score and outcome models.41
Because our findings arise from a single empirical example, we do not know the true
treatment effect for any population, and we are uncertain whether treatment effect
hetereogeneity existed. Further, we caution that the substantive findings reported here serve
only as an example and do not represent our final substantive results. Nonetheless, this study
highlights the importance of deciding clearly which population and treatment effect estimate
are of interest. For example, if the research question involves the effect of a treatment on
those currently receiving it, then the “treatment effect in the treated” (ATT) is of interest. If
there is not a match for every treated observation, then researchers face a trade-off between
incomplete matching on the one hand, which restricts the sample and therefore the study
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population, and extrapolation through weighting on the other. If all assumptions are met,
including no unmeasured confounding, then weighting results in the better estimate of the
treatment effect in the treated. If some assumptions are violated, the matched estimate may
be more robust because (1) the matched sample inherently excludes extreme observations
and (2) the matched estimate depends only on similarities between propensity score values,3
whereas the weighted estimate depends on exact propensity score values.42 In some cases,
multiple estimates may be relevant, especially if propensity score distributions differ greatly
between treatment groups before adjustment, matching is incomplete, the treatment effect is
heterogeneous, or there is interest in more than one population.
One way of presenting multiple treatment effect estimates is to stratify by the propensity
score, complementing the more general information provided by estimates of the marginal
treatment effect in specific populations. Stratification allowed us to describe a specific, U-
shaped pattern of apparent treatment effect heterogeneity. In substantive studies, clinical
interpretation can be aided by using variables other than the propensity score to describe
subgroups with different clinical outcomes. For example, in the current study, the
augmentation recipients in the highest propensity score decile were characterized by their
tolerance for longer initial treatment and by milder depressive severity after initial
treatment.19
Conclusion
Using data from the STAR*D study, we implemented propensity score matching and
weighting methods, both intended to measure the treatment effect in patients who received
augmentation with a second antidepressant. We found that the two methods yielded different
samples and treatment effect estimates due to incomplete matching, sensitivity of the
weighted estimates to extreme observations, and apparent treatment effect heterogeneity. In
propensity score analysis, crucial steps include identifying the population and treatment
effect estimate of interest, selecting an appropriate propensity score implementation method,
and conducting and presenting results from sensitivity analyses. Weighted estimation in
particular should always include sensitivity analyses relating to influential observations,
such as those treated contrary to prediction.
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• Propensity-score-matched and -weighted treatment effect estimates differed in
this setting.
• The primary causes were incomplete matching, sensitivity of weighted estimates
to extreme observations, and possibly treatment effect heterogeneity.
• In propensity score analysis, crucial steps include identifying the population and
treatment effect of interest, selecting an appropriate implementation method,
and conducting and reporting sensitivity analyses.
• Weighted estimation should always include sensitivity analyses relating to
influential observations.
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Figure 1. Propensity Score Distribution in the Augment and Switch Groups Before Propensity
Score Application, After Matching, and After Weighting
The figure, based on kernel density estimation, shows distributions of propensity scores
estimated using logistic regression. Horizontal axes indicate ranges of propensity score
values. Weights are for the treatment effect in the medication augmentation group.
Ellis et al. Page 11













Figure 2. Sensitivity of Weighted Estimates to Truncation of Weights and to Exclusion of
Observations with Extreme Propensity Scores
CI=confidence interval; RR=risk ratio. The figure shows RRs for remission based on
estimated propensity scores that were applied using standardized mortality ratio weights.
Percentile cutoffs are relative to the propensity score distribution in the medication switch
group. Truncation means that weights below the lower cutoff were increased to equal the
lower cutoff, and weights above the higher cutoff were decreased to equal the higher cutoff.
Exclusion means that observations outside the indicated range were omitted from the
analysis. Box size indicates relative precision. Lines indicate 95% confidence intervals.
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Figure 3. Heterogeneity of Treatment Effect
CI=confidence interval; RR=risk ratio. The figure shows RRs for remission after restricting
to the common support region and stratifying by the estimated propensity score. Box size
indicates relative precision. Lines indicate 95% confidence intervals.
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